337 related articles for article (PubMed ID: 30296685)
1. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
[TBL] [Abstract][Full Text] [Related]
3. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
6. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice.
Li Z; Liu C; Zhou Z; Hu L; Deng L; Ren Q; Qian H
Pharmacol Res; 2020 Mar; 153():104679. PubMed ID: 32014571
[TBL] [Abstract][Full Text] [Related]
7. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold.
Li Z; Ren Q; Wang X; Zhou Z; Hu L; Deng L; Guan L; Qiu Q
Bioorg Chem; 2019 Nov; 92():103209. PubMed ID: 31487621
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
[TBL] [Abstract][Full Text] [Related]
10. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
11. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1.
Yang J; Gu E; Yan T; Shen D; Feng B; Tang C
Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Wang X; Xu X; Yang J; Qiu Q; Qiang H; Huang W; Qian H
Bioorg Med Chem; 2015 Oct; 23(20):6666-72. PubMed ID: 26420383
[TBL] [Abstract][Full Text] [Related]
15. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Evans JL; Lin JJ; Goldfine ID
Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents.
Li Z; Xu X; Liu R; Deng F; Zeng X; Zhang L
Bioorg Med Chem; 2018 Aug; 26(15):4560-4566. PubMed ID: 30082106
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
[TBL] [Abstract][Full Text] [Related]
18. Design, development and evaluation of novel dual PPARδ/PPARγ agonists.
Gathiaka S; Nanayakkara G; Boncher T; Acevedo O; Wyble J; Patel S; Patel A; Shane ME; Bonkowski B; Wieczorek J; Rong Y; Huggins K; Smith F; Amin RH
Bioorg Med Chem Lett; 2013 Feb; 23(3):873-9. PubMed ID: 23273519
[TBL] [Abstract][Full Text] [Related]
19. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.
Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L
Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092
[TBL] [Abstract][Full Text] [Related]
20. Multitargeted bioactive ligands for PPARs discovered in the last decade.
Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]